Protocol for a multicentre, prospective observational study of elective neck dissection for clinically node-negative oral tongue squamous cell carcinoma (END-TC study)

Souichi Yanamoto 1, Yasuyuki Michi,2 Mitsunobu Otsuru,1 Toru Inomata,3 Hideki Nakayama,4 Takeshi Nomura,5 Takumi Hasegawa,6 Yoshiho Yamamura,7 Shin-ichi Yamada,8 Jingoh Kusukawa,9 Nobuhiro Yamakawa,10 On Hasegawa,11 Michihiro Ueda,12 Yoshimasa Kitagawa,13 Akimitsu Hiraki,14 Yoshihiro Hasegawa,15 Yoichi Ohiro,16 Wataru Kobayashi,17 Seiji Asoda,18 Takanori Kobayashi,19 Mitsuyoshi lino,20 Masayuki Fukuda,21 Naomi Ishibashi-Kanno,22 Koji Kawaguchi,23 Reona Aijima,24 Kazuma Noguchi,25 Masaya Okura,26 Akira Tanaka,27 Tsuyoshi Sugiuara,28 Yukari Shintani,29 Kazuhiro Yagihara,30 Masashi Yamashiro,31 Yoshihide Ota,32 Akihiro Miyazaki,33 Akinori Takeshita,34 Hitoshi Kawamata,35 Iwabuchi Hiroshi36 Kenichiro Uchida,37 Masahiro Umeda,1 Hiroshi Kurita,8 Tadaaki Kirita10

ABSTRACT

Introduction In early-stage oral tongue squamous cell carcinoma (OTSCC), elective neck dissection (END) is recommended when occult lymph node metastasis is suspected; however, there is no unanimous consensus on the risks and benefits of END in such cases. The management of clinically node-negative (cN0) OTSCC remains controversial. This study, therefore, aimed to evaluate the efficacy of END and its impact on the quality of life (QoL) in patients with cN0 OTSCC.

Methods and analysis This is a prospective, multicentre, non-randomised observational study. The choice of whether to perform END at the same time as resection of the primary tumour is based on institutional policy and patient preference. The primary endpoint of this study is 3-year overall survival. The secondary endpoints are 3-year disease-specific survival, 3-year relapse-free survival and the impact on patient QoL. Propensity score-matching analysis will be performed to reduce selection bias.

Ethics and dissemination This study was approved by the Clinical Research Review Board of the Nagasaki University. The protocol of this study was registered at the University Hospital Medical Information Network Clinical Trials Registry. The datasets generated during the current study will be available from the corresponding author on reasonable request. The results will be disseminated internationally, through scientific and professional conferences and in peer-reviewed medical journals.

Trial registration number UMIN000027875.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The strength of this study is the ability to evaluate the efficacy of elective neck dissection for clinically node-negative oral tongue squamous cell carcinoma in a large multicentre nationwide prospective observational study.
⇒ This study is being conducted by the joint research committee of the Japanese Society of Oral Oncology and involves institutions throughout Japan.
⇒ The limitation of this study is that it may not provide stronger evidence due to participants not being randomly assigned to an intervention or control group.
⇒ This prospective observational study is more relevant to clinical practice and more pragmatic to deliver without changing standard of care or ignoring clinician/patient preference.
⇒ Potential confounding differences at baseline due to non-randomisation and the selection biases associated with institutional policy and patient preferences are corrected for with a statistical technique called propensity score matching.

INTRODUCTION

Head and neck cancer is the seventh most common cancer worldwide, accounting for an estimated 888 000 new cases in 2018.1 Almost 50% of head and neck cancers arise in the oral cavity.1 Most oral cancers are squamous cell carcinoma, and regional lymph node metastasis of oral squamous
cell carcinoma is a useful prognostic factor of treatment outcomes.5 6 Early detection of regional lymph node metastases in early-stage oral squamous cell carcinoma contributes to improved survival rates. Occult lymph node metastases are relatively common, even when the pretreatment diagnosis is negative for lymph node metastasis, with a varying frequency between institutions.7 8 In cases where no involvement of the cervical lymph nodes is observed either clinically or via imaging, elective neck dissection (END) is recommended when occult lymph node metastasis is suspected. However, there is no unanimous consensus on the risks and benefits of END in such cases. Patients who undergo neck dissection have a low risk of spinal accessory-nerve injury, trapezius-muscle dysfunction and upper-limb elevation problems; therefore, unnecessary neck dissection should be avoided to improve patients’ quality of life (QoL). Hence, reliable predictors are needed to identify patients with a true node-negative neck.

The depth of invasion (DOI) of the tumour is a predictor of cervical regional lymph node metastasis.9 Many researchers have examined DOI as a prognostic factor in oral squamous cell carcinoma.5 6–8 A large, randomised phase III trial conducted by D’Cruz et al9 revealed that the addition of END to partial glossectomy significantly improved overall survival (OS) in patients with early-stage oral squamous cell carcinoma, regardless of the degree of DOI. Furthermore, subgroup analysis revealed that patients with a pathological DOI of 3 mm or less benefited from END in addition to partial glossectomy.9 However, there is some scepticism regarding the generalisability of this randomised control trial (RCT) to clinical practice. In general, most cases of lymph node recurrence are curatively operable if detected early; however, in that RCT,9 18% of the enrolled patients were deemed inoperable, which does not eliminate the impact of problems with medical resources or diagnostic systems at a single institution.

Previous meta-analyses of RCTs only incorporated RCTs with OS or disease-specific survival (DSS) as outcomes; hence, it is not surprising that END was deemed clinically significant in all of them.10–12 However, several questions remain. Does neck dissection decrease QoL in truly node-negative patients? In addition, is it acceptable to generalise the results of an RCT of a patient population with low generalisability that participates in an RCT? The appropriate neck management for clinically node-negative (cN0) oral tongue squamous cell carcinoma (OTSCC) remains controversial.

Therefore, we conceived a prospective observational study to determine the efficacy of END in cN0 OTSCC, relevant to clinical practice and relatively unrestricted, by performing curative treatment without randomisation after enrollment and with uniform follow-up. Furthermore, the results of this study may provide new outcome-oriented insights into the efficacy of END for cN0 OTSCC, by focussing on patient QoL.

**Objectives**

The objective of this study is to evaluate the efficacy of END and its impact on QoL in patients with cN0 OTSCC.

**METHODS AND ANALYSIS**

**Study design**

This prospective study was designed as a multicentre, nonrandomised observational study for evaluation of the efficacy of END for patients with cN0 OTSCC. The methodology was developed according to the Strengthening the Reporting of Observational Studies in Epidemiology and standards for reporting diagnostic accuracy statements. The protocol was written based on the Standard Protocol Items: Recommendations for Interventional Trials checklist. Figure 1 contains the study flow chart.

**Study setting**

This multicentre study is being conducted by the joint research committee of the Japanese Society of Oral Oncology (JSOO). The participating institutions are JSOO-certified high-level clinical facilities in the provision of treatment for oral cancer and accept compliance with the study protocol. The research secretariat solicited the participation of such facilities. The participating facilities are Nagasaki University, Tokyo Medical and Dental University, Kumamoto University, Nippon Dental University, Tokyo Dental College, Kobe University, Tokushima University, Shinsyu University, Kurume University, Nara Medical University, Tokyo Medical University, Hokkaido Cancer Center, Hokkaido University, Fukuoka Dental College, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Hirosaki University, Keio University, Nagaoka Red Cross Hospital, Yamagata University, Akita University, Tsukuba University, Tsurumi University, Saga University, Hyogo Medical University, Saiseikai Mutsuoka General Hospital, Kagoshima University, Wakayama Medical University, Saitama Prefectural Cancer Centre, NTT Medical Centre Tokyo, Tokai...
Psychosis or psychiatric symptoms that complicate the patient's condition.

History of treatment for malignant tumours of the head and neck area.

No apparent distant metastasis.

Aged ≥20 years at the time of informed consent acquisition.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Patient operable.

Signed informed consent.

Inclusion criteria

Eligibility criteria

► Histologically confirmed OTSCC.
► cN0 OTSCC based on the Union for International Cancer Control eighth edition TNM classification.
► No apparent distant metastasis.
► Aged ≥20 years at the time of informed consent acquisition.
► Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
► Patient operable.
► Signed informed consent.

Exclusion criteria

► History of treatment for malignant tumours of the head and neck area.
► History of multiple cancers with a disease-free period of less than 5 years at the date of registration.
► Psychosis or psychiatric symptoms that complicate participation in the study.

Interventions

All patients are diagnosed with enhanced CT or MRI at the minimum. Surgical treatment is performed with the patient under general anaesthesia. Resection of the primary tumour was performed to ensure adequate histopathological margins (≥5 mm) in all planes. The choice of whether to perform END at the same time as resection of the primary tumour is based on institutional policy and patient preference. For the END procedure, dissection of at least levels I–III is recommended; however, the type of neck dissection is at the surgeon’s discretion. In the group that undergo resection of the primary tumour alone, comprehensive neck dissection (dissection of levels I–V) is indicated when cervical lymph node metastases are detected during follow-up. If there are high-risk factors for postoperative recurrence, such as positive margins and/or extranodal extension, additional resection of the primary tumour, postoperative radiation therapy (RT) or chemoradiation therapy (CRT) may be recommended.

Outcomes

The primary endpoint of this study is OS. The OS will be calculated from the date of curative treatment (the date of surgery or the end date of postoperative RT/CRT) to the date of death from any cause and censored at the last follow-up day at which the patient is alive. The RFS will be calculated from the date of curative treatment to the date of any relapse or death from any cause and censored at the last follow-up day at which the patient is alive and relapse-free. The impact of QoL is assessed by using the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) questionnaire. The FACT-H&N consists of 11 items specific to head and neck cancer, an addition to the FACT-General, a QoL questionnaire for cancer in general.

Follow-up and assessment schedule

Participants will be followed up for 3 years after the date of curative treatment. The date of curative treatment is the date of surgery or the end date of postoperative RT/CRT. Patients will be followed up every month for the first year, every 2 months in the second year, and every 3 months thereafter. Palpation with/without ultrasonography will be performed at each follow-up visit. In addition, enhanced CT or MRI of the head and neck will be performed every 3 months after curative treatment and chest X-ray examination or CT every 6 months thereafter. Furthermore, the FACT-H&N questionnaire will be used for assessment 1, 3, 6, 12, 24 and 36 months after curative treatment. Simultaneously, the DASH questionnaire will be used for assessment 36 months after curative treatment. The data collection schedule is presented in table 1.

Sample size

The primary endpoint of this study is 3-year OS, which was used to calculate the required sample size. According to a previous RCT, the 3-year OS rate of patients who underwent resection of the primary tumour alone was 67.5%, and the 3-year OS rate of patients who underwent END was 80.0%. The sample size required to detect differences between two independent proportions was calculated by using the SWOG statistical tool (https://stattools.crab.org/), with 80% power and a two-sided significance level of α=0.05. Accordingly, 199 participants are required in each group. As the rate of END for early-stage tongue cancer in Japan is approximately 25%, the total sample size should be 800. Since this study is a prospective observational study, the sample size should be acceptable in actual clinical practice, but the sample size was set to be statistically advantageous by referring to previous prospective studies. In addition, the drop-out rate was not taken into account.

Recruitment

Participant recruitment started at the participating facilities in November 2017 and will continue to October 2022. The planned study period is November 2017 to October 2026. All patients with cN0 OTSCC are screened for eligibility and asked to provide written informed consent (see online supplemental file). Principal investigator of the participating institutions will train the participants to
explain the purpose and details of the study in the local language, obtain written informed consent, and record relevant information on QoL questionnaire. Participants are informed that they have the right to withdraw from the study at any time without having to give a reason.

**Patient and public involvement**

No patient involved.

**Data collection and management**

Data collection will be performed by using the Alliance Clinical Research Support System Electronic Data Capture (EDC) software of the University Hospital Clinical Trial Alliance. Data entry into the case report forms will be performed by investigators using the EDC software at each participating facility. Following the completion of the study, the fixed data will be exported, deleted from the EDC, and stored in a public data repository.

**Statistical analysis**

Clinicopathological characteristics of participants will be compared between the primary resection-only group and the primary resection with END group by using the χ² or Fisher’s exact test for categorical variables and the t-test or Mann-Whitney U test for continuous variables. Cumulative OS, DSS and RFS rates will be estimated with the Kaplan-Meier method and compared with the log-rank test, followed by multivariate Cox proportional hazards analyses.

Propensity score-matching analysis will be performed to reduce selection biases associated with the institutional policy and patient preferences. The propensity score will be computed via logistic regression for each patient based on the presumed covariates, which includes age, sex, ECOG performance status, smoking status, alcohol consumption, clinical T stage, clinical DOI and oral care management. Propensity score matching will be performed with 1:1 nearest-neighbour matching and a calliper value equal to a width of 0.25 for the SD of the propensity score.

All data analyses will be performed by using IBM SPSS Statistics for Windows V.24.0 (Japan IBM). Two-tailed p values <0.05 will be defined as statistically significant throughout the analyses.

**Data sharing**

The study investigators will have full access to and ownership of all data. Deidentified data will be made available to interested outside investigators for additional analyses on reasonable request, following reports of primary outcomes, and with an appropriate data use agreement. Anonymised patient data will be made available via the data coordinating centre (Centre for Clinical Research, Shinshu University Hospital; tcend-project@umin.org) to qualified investigators who submit an approved research proposal. The anonymity, reliability and process of the data collected will be explained in the consent form, explaining that the data will be used only for the purpose of the specific study and will be destroyed after completion. To maintain the confidentiality and anonymity of the participants, the identities of the participants will not be mentioned at all. Participants will be coded so that no one but the principal investigator will know whose data are being used. Only the principal investigator will have access to the data.

**Perspective/conclusion**

Although the superiority of END over primary resection alone in early-stage tongue cancer has been demonstrated by several meta-analyses or systematic reviews, there is resistance to generalising and interpreting the results of only a few RCTs. In fact, several problems have been pointed out. First, there is the issue of the difference in the significance of DOI according to the primary site of oral cavity, in other words, whether a DOI of 3 mm
for tongue cancer and 3 mm for oral floor cancer can be considered in the same way. In addition, the issue of the high rate of neck recurrence, in the RCT by India,6 43% of the primary resection-only group had neck recurrence, and 18% of them were inoperable. Furthermore, the randomisation of END or not may result in a limited number of study participants, which may lead to a study with low external validity, low generalisability, which is the most feared aspect of RCTs. Therefore, a prospective observational study was conceived to see what would happen if the patients were treated without randomisation and uniformly followed up.

Perspectives of this study may clarify the incidence of occult neck metastases in Japan. It may be possible to set a cut-off value for DOI to determine the superiority of END in tongue cancer. It may be possible to clarify the impact of END on QoL. Ultimately, our results will contribute to determining clear criteria for END.

**ETHICS AND DISSEMINATION**

This study was approved by the Clinical Research Review Board of Nagasaki University (No. 17061944) in 21 June 2017. At the same time, the protocol of this study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000027875). Details are available at the following address: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031938.

Any protocol changes that impact the study conduct and/or participant risk–benefit profile, including changes in the objectives, design, sample size, participant characteristics, staff or important administrative aspects, require approval from the relevant institutional review board. Minor protocol corrections and/or clarifications that do not affect study conduct or the participant risk–benefit profile are viewed as unimportant administrative changes and documented internally. This protocol was revised to a V.2 on 8 June 2020, to extend the case enrolment period.

The findings of this study will be disseminated internationally through scientific and professional conferences and in peer-reviewed medical journals.

**Author affiliations**

1Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
2Department of Oral and Maxillofacial Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Japan
3Department of Oral and Maxillofacial Surgery, The Nippon Dental University, Tokyo, Japan
4Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
5Department of Oral Oncology, Oral and Maxillofacial Surgery, Tokyo Dental College, Tokyo, Japan
6Department of Oral and Maxillofacial Surgery, Kobe University, Kobe, Japan
7Department of Oral Surgery, Tokushima University, Tokushima, Japan
8Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
9Dental and Oral Medical Center, Kurume University School of Medicine, Kurume, Japan
10Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan
11Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Tokyo Medical University, Tokyo, Japan
12Department of Oral Surgical Oncology, National Hospital Organisation Hokkaido Cancer Center, Sapporo, Japan
13Department of Oral and Maxillofacial Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
14Department of Oral and Maxillofacial Surgery, Hokkaido University, Sapporo, Japan
15Department of Oral and Maxillofacial surgery, Hirosaki University, Hirosaki, Aomori, Japan
16Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan
17Department of Dentistry and Oral Surgery, Nagaoka Red Cross Hospital, Nagaoka, Japan
18Department of Dentistry and Oral Surgery, Yamashina Red Cross Hospital, Sapporo, Japan
19Department of Dentistry, Yamagata University, Yamagata, Japan
20Department of Dental and Oral Medicine, Akita University, Akita, Japan
21Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
22Department of Oral and Maxillofacial Surgery, Tsurumi University, Yokohama, Japan
23Department of Oral and Maxillofacial Surgery, Saga University, Saga, Japan
24Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Nishinomiya, Japan
25Department of Dentistry and Oral Surgery, Saiseikai Matsusaka General Hospital, Matsusaka, Mie, Japan
26Department of Oral and Maxillofacial Surgery, The Nippon Dental University, Niigata, Japan
27Department of Maxillofacial Diagnostic and Surgical Science, Kagoshima University, Kagoshima, Japan
28Department of Oral and Maxillofacial Surgery, Wakeyama Medical University, Wakayama, Japan
29Department of Oral Surgery, Saitama Cancer Center, Saitama, Japan
30Department of Dentistry and Oral Surgery, NTT Medical Center Tokyo, Tokyo, Japan
31Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan
32Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
33Department of Oral and Maxillofacial Surgery II, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
34Department of Oral and Maxillofacial Surgery, Dokkyo Medical University, Shimotsuga-gun, Tochigi, Japan
35Department of Oral and Maxillofacial Surgery, Nara Medical University, Nara, Japan
36Department of Oral and Maxillofacial Surgery, Kagawa University, Iwakuni, Kagawa, Japan
37Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

**Acknowledgements** The authors thank Yoshiko Takagi, Toshiko Kinoshita, and Kaori Kobayashi, Centre for Clinical Research, Shinshu University Hospital for project and data management. The authors also thank Editage (www.editage.com) for English language editing.

**Contributors** MU is the principal investigator of this study. The idea and concept were developed by SY, MU, HK and TK. Data collection was performed by YM, MO, TI, HW, TW, YY, SY, JK, NY, OH, MU, YK, AH, TH, YO, WK, SA, TK, MI, MF, NI-K, KK, RA, KN, MO, AT, TS, YS, KY, MY, YO, AM, AT, HK, IH and KU. Data analysis was performed by SY and HK. The first draft of the manuscript was written by SY, and all authors commented on the previous versions of the manuscript. All authors contributed to the study conception and design and have read and approved the final manuscript.

**Funding** This research is supported by Grants-in-Aid for Scientific Research of the Japan Society for the Promotion of Science (grant numbers 18K09818 and 21K10098). The trial sponsor is MU, principal investigator, an individual member of the Joint Research Committee of the Japanese Society of Oral Oncology, who is responsible for all or any of the planning, management and funding of the study.

**Disclaimer** The funder will have no role in study design, data collection and analysis, manuscript preparation, or decision to publish.
REFERENCES